Compare Bristol-Myers Squibb Co (BMY) vs Bit Digital Inc (BTBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Bit Digital Inc — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Bit Digital Inc trades at $1.65 (market cap $581.34M). The key difference: Bristol-Myers Squibb Co is far larger — about 200.1× Bit Digital Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Bit Digital Inc pays none. Which is the better fit depends on your goals.
| BMY | BTBT | |
|---|---|---|
Market Cap | $116.30B | $581.34M |
Sector | Health | Technology |
52-Week High | $62.37 | $4.22 |
52-Week Low | $42.60 | $1.27 |
Enterprise Value | $152.24B | $870.65M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
BTBT trades at $1.64, down 2.96% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $80.32 million in 2025 with a -145.45% net income margin, missing earnings expectations for three consecutive quarters. Recent strategic moves include a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase to bolster its asset position.
Despite 100% analyst buy ratings, BTBT faces significant fundamental challenges with persistent losses and negative cash flow from operations. The stock's appeal hinges on turnaround execution and crypto market recovery, but high volatility and operational risks warrant caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
